Results 11 to 20 of about 3,878 (166)

Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial. [PDF]

Acta Anaesthesiol Scand
ABSTRACT Background Despite developments in advanced life support, outcomes after out‐of‐hospital cardiac arrest (OHCA) remain poor. Levosimendan, a calcium‐sensitizing inodilator commonly used in heart failure, has shown beneficial effects in several experimental models and anecdotal clinical cases of cardiac arrest. The Levosimendan in Cardiac Arrest
Rysz S, Flam B, Hedberg M, Galmén K, Mårtensson J, Djärv T, Jonsson Fagerlund M.   +6 more
europepmc   +2 more sources

PERIOPERATIVE USE OF LEVOSIMENDAN IN PATIENTS WITH SEVERE LEFT VENTRICULAR DYSFUNCTION UNDERGOING CARDIAC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS [PDF]

Ain Shams Medical Journal, 2022
Background: Levosimendan is a calcium-sensitizing ionodilator. However, the current level of clinical evidence is insufficient to determine the clinical value of levosimendan in patients with severe left ventricular dysfunction subjected to cardiac ...
Ramy Reda, Ahmed Fouad, Osama Abd Elhamed, Ahmed Mansour   +3 more
doaj   +1 more source

Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy

Journal of Cardiothoracic Surgery, 2020
Background Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In
Juan José Jiménez-Rivera, Andrea Álvarez-Castillo, Jorge Ferrer-Rodríguez, José Luis Iribarren-Sarrías, Martín Jesús García-González, Pablo Jorge-Pérez, Juan Lacalzada-Almeida, Rosalía Pérez-Hernández, Javier Montoto-López, Rafael Martínez-Sanz   +9 more
doaj   +1 more source

Influence of timing of Levosimendan administration on outcomes in cardiac surgery

Frontiers in Cardiovascular Medicine, 2023
PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Christian Berger, Liubov Penkova, Herko Grubitzsch, Bernhard Haller, Alexander Meyer, Alexander Meyer, Matthias Heringlake, Michael Sander, Joachim M. Erb, Felix Balzer, Sascha Treskatsch   +13 more
doaj   +1 more source

Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock

Frontiers in Cardiovascular Medicine, 2022
BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen, Wei-Chieh Lee, Wei-Chieh Lee, Po-Jui Wu, Hsiu-Yu Fang, Yen-Nan Fang, Huang-Chung Chen, Meng-Shen Tong, Pei-Hsun Sung, Chieh-Ho Lee, Wen-Jung Chung   +10 more
doaj   +1 more source

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure

BMC Anesthesiology, 2011
Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room.
Suominen Pertti K
doaj   +1 more source

Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Critical Care, 2020
Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme, Matthias Jacquet-Lagrèze, Matteo Pozzi, Felix Achana, Xavier Armoiry, Jean-Luc Fellahi   +5 more
doaj   +1 more source

Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: A perspective, multi-center, real-world registry

Frontiers in Cardiovascular Medicine, 2022
ObjectiveAcute heart failure (AHF) is associated with high mortality. Levosimendan, an inodilator, has proved to increase cardiac output and exert renoprotective effect in AHF.
Han Zhang, Li Jiang, Rui Fu, Ping Qin, Xuan Zhang, Tao Tian, Guang-xun Feng, Yan-min Yang   +7 more
doaj   +1 more source

Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

PLoS ONE, 2020
INTRODUCTION:Levosimendan is approved for acute heart failure. Within this context, pulmonary hypertension represents a frequent co-morbidity. Hence, the effects of levosimendan on segmental pulmonary vascular resistance (PVR) are relevant.
Annette Dorothea Rieg, Said Suleiman, Nina Andrea Bünting, Eva Verjans, Jan Spillner, Heike Schnöring, Sebastian Kalverkamp, Thomas Schröder, Saskia von Stillfried, Till Braunschweig, Gereon Schälte, Stefan Uhlig, Christian Martin   +12 more
doaj   +1 more source

Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury? [PDF]

PLoS ONE, 2013
INTRODUCTION: Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver. Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of ...
Peter Onody, Rita Stangl, Andras Fulop, Oliver Rosero, David Garbaisz, Zsolt Turoczi, Gabor Lotz, Zoltan Rakonczay, Zsolt Balla, Viktor Hegedus, Laszlo Harsanyi, Attila Szijarto   +11 more
doaj   +1 more source